Work

DATO-Base: A phase II study of DATOpotamab deruxtecan for patients with breast cancer brain metastases or leptomeningeal disease.

Year: 2025

Type: article

Study design: Study Protocol

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2025.43.16_suppl.tps1134

Authors: Paolo Tarantino, Tianyu Li, Clare Strickland, Michelle DeMeo, Leilani Anderson, Esther Pasternak, Carey K. Anders, Manmeet Singh Ahluwalia, Reshma L. Mahtani, Liangge Hsu, Sarah Ossing, Nabihah Tayob, Sara M. Tolaney, Nancy U. Lin, Sarah L. Sammons

Institutions: Dana-Farber Cancer Institute, Duke University, Duke Cancer Institute, Baptist Hospital of Miami, Baptist Health South Florida, Brigham and Women's Hospital, Harvard University

Language: English

Topic: Brain Metastases and Treatment

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4410805314

FWCI: 1.169

Cites:

Cited by: 2

Related to: 10